Results: Liver enzymes: serum glutamic pyruvic transaminase and serum glutamic oxaloacetic transaminase
were found significantly higher among the petrol filling attendants in comparison to the control group, except serum alkaline phosphatase which was although higher in petrol filling attendants but statistically insignificant between the two groups.
On applying the unpaired t-test, we found that adverse fetal outcomes were significantly associated with rising serum bilirubin levels of more than 11 mg/dL, serum glutamic oxaloacetic transaminase
(SGOT) and serum glutamic pyruvic transaminase (SGPT) of more than 1000 IU/L, and a platelet count of less than 85.
35 ng/mL; creatinine kinase-MB (CKMB) was 288 U/L, N-terminal B-type natriuretic peptide was 3347 pg/mL, glutamic oxaloacetic transaminase
was 578 U/L, and lactic acid was 2.
3] 8 Urine alb 9 Potassium meq 4 10 HIV 11 Serum r amylase 12 Total Bilirubin/Direct Bilirubin 13 SGOT/SGPT * 14 Serum Albumin 15 Alkaline phosphatase 16 Stool micro * SGOT--Serum Glutamic Oxaloacetic Transaminase
, SGPT--Serum Glutamic Pyruvate Transaminase.
In all patients, the levels of Serum alanine aminotransferase (ALT) and serum glutamic oxaloacetic transaminase
(SGOT), Bilirubin level were done by using Advia 1800 chemistry Analyzer.
8 mmol/L, serum glutamic pyruvic transaminase 2 695 IU/L, serum glutamic oxaloacetic transaminase
7 559 IU/L and serum creatine phosphokinase 1 967 IU/L.
Blood serum was collected after centrifugation (3,000 rpm for 10 min) and stored at -70[degrees]C in order to analyze the hematocrit (HCT), hemoglobin (Hb), glutamic oxaloacetic transaminase
(GOT) and glutamic pyruvic transaminase (GPT).
The serum glutamic oxaloacetic transaminase
(GOT) and glutamic pyruvic transaminase (GPT) were measured by the IFCC method (Hitachi 917[R] device, Roche Diagnostics, Florida, USA).
Fasting blood glucose (FBG), glycated hemoglobin (HbAlc), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), serum glutamic oxaloacetic transaminase
(SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (ALP), blood urea nitrogen (BUN) and creatinine levels were measured at baseline and after 2 months study treatment.
The results of liver function tests were as follows: total bilirubin level 268 [micro]mol/l (direct 166 [micro]mol/l), serum glutamic oxaloacetic transaminase
32 IU/l, serum glutamic pyruvate transaminase 40 IU/l, serum alkaline phosphatase 1 270 IU/l and gamma-glutamyl transpeptidase 760 IU/l.
Serum glutamic oxaloacetic transaminase
(SGOT) is an enzyme, majorly present in the heart muscle, liver tissues, skeletal muscles, and kidneys.
Two-thirds of the patients had an ST-elevation MI; the rest had symptoms compatible with an AMI with electrocardiographic changes accompanied by an increase in serum glutamic oxaloacetic transaminase
or creatine phosphokinase.